Research agenda evaluating measurement-based care for opioid use disorder among patients with co-occurring depressive disorders.
作者信息
Ghitza Udi E
机构信息
Center for the Clinical Trials Network (CCTN), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), US Department of Health and Human Services (HHS), Bethesda, MD, United States.
出版信息
Front Psychiatry. 2025 Aug 7;16:1624642. doi: 10.3389/fpsyt.2025.1624642. eCollection 2025.
Abstract
摘要
相似文献
1
Research agenda evaluating measurement-based care for opioid use disorder among patients with co-occurring depressive disorders.评估共病抑郁症患者阿片类物质使用障碍基于测量的照护的研究议程。
Front Psychiatry. 2025 Aug 7;16:1624642. doi: 10.3389/fpsyt.2025.1624642. eCollection 2025.
2
Use of Behavioral Health Treatment Among Parenting Women With Opioid Use Disorder in the United States.
J Obstet Gynecol Neonatal Nurs. 2024 Jul;53(4):355-367. doi: 10.1016/j.jogn.2024.01.004. Epub 2024 Feb 2.
3
Prevalence of Axis-1 psychiatric (with focus on depression and anxiety) disorder and symptomatology among non-medical prescription opioid users in substance use treatment: systematic review and meta-analyses.在物质使用治疗中，非医疗处方类阿片类药物使用者的轴 1 精神（重点关注抑郁和焦虑）障碍和症状的流行情况：系统评价和荟萃分析。
Addict Behav. 2014 Mar;39(3):520-31. doi: 10.1016/j.addbeh.2013.11.022. Epub 2013 Dec 2.
4
Screening for opioid use disorder and co-occurring depression and post-traumatic stress disorder in primary care in New Mexico.在新墨西哥州的初级保健中筛查阿片类药物使用障碍以及共病的抑郁和创伤后应激障碍。
Addict Sci Clin Pract. 2023 Jan 27;18(1):6. doi: 10.1186/s13722-023-00362-5.
6
Assessing Substance Use Disorder Symptoms with a Checklist among Primary Care Patients with Opioid Use Disorder and/or Long-Term Opioid Treatment: An Observational Study.使用检查表评估患有阿片类药物使用障碍和/或长期阿片类药物治疗的初级保健患者的物质使用障碍症状：一项观察性研究。
J Gen Intern Med. 2024 Sep;39(12):2169-2178. doi: 10.1007/s11606-024-08845-0. Epub 2024 Jul 1.
7
Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision.受刑事司法监管的阿片类药物使用者中情绪障碍的患病率、诊断率和治疗率
Subst Use Misuse. 2018 Jul 29;53(9):1519-1528. doi: 10.1080/10826084.2017.1416400. Epub 2018 Jan 15.
8
Polysubstance Use, Mood Disorders, and Chronic Conditions With Anxiety in Opioid Patients.阿片类药物使用者的共病物质使用、心境障碍和伴有焦虑的慢性疾病。
West J Nurs Res. 2022 Dec;44(12):1088-1099. doi: 10.1177/01939459211031988. Epub 2021 Jul 23.
9
Evaluating a longitudinal mediation model of perceived stress, depressive symptoms, and substance use treatment outcomes.评估感知压力、抑郁症状和物质使用治疗结果的纵向中介模型。
Psychol Addict Behav. 2020 Sep;34(6):660-668. doi: 10.1037/adb0000581. Epub 2020 Apr 16.
10
Providers' Experiences and Perspectives in Treating Patients With Co-Occurring Opioid and Stimulant Use Disorders in the Hospital.医疗机构提供者治疗同时患有阿片类药物和兴奋剂使用障碍患者的经验和观点。
Subst Use Addctn J. 2024 Apr;45(2):250-259. doi: 10.1177/29767342231221060. Epub 2024 Jan 9.
本文引用的文献
1
Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus.实现基于测量的护理（MBC）治疗阿片类药物使用障碍（OUD）的工具：达成共识。
Addict Sci Clin Pract. 2024 Feb 28;19(1):14. doi: 10.1186/s13722-024-00446-w.
2
Why Deaths of Despair Are Increasing in the US and Not Other Industrial Nations-Insights From Neuroscience and Anthropology.为什么美国的“绝望致死”人数在增加，而其他工业国家却没有——神经科学和人类学的见解。
JAMA Psychiatry. 2022 Apr 1;79(4):368-374. doi: 10.1001/jamapsychiatry.2021.4209.
3
Summary of the clinical practice guideline for the treatment of depression across three age cohorts.三个年龄队列的抑郁症治疗临床实践指南概述。
Am Psychol. 2022 Sep;77(6):770-780. doi: 10.1037/amp0000904. Epub 2021 Nov 29.
4
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.描述一个具有全国代表性的美国商业保险队列中，延长释放丁丙诺啡的起始使用、持续使用和停止使用情况。
Drug Alcohol Depend. 2021 Aug 1;225:108764. doi: 10.1016/j.drugalcdep.2021.108764. Epub 2021 May 21.
5
Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses.药物再利用治疗阿片类药物使用障碍：计算预测、临床证实和作用机制分析的整合。
Mol Psychiatry. 2021 Sep;26(9):5286-5296. doi: 10.1038/s41380-020-01011-y. Epub 2021 Jan 11.
6
Retention of patients in opioid substitution treatment: A systematic review.阿片类药物替代治疗中患者的保留情况：系统评价。
PLoS One. 2020 May 14;15(5):e0232086. doi: 10.1371/journal.pone.0232086. eCollection 2020.
7
Personalizing the Treatment of Substance Use Disorders.个性化物质使用障碍的治疗
Am J Psychiatry. 2020 Feb 1;177(2):113-116. doi: 10.1176/appi.ajp.2019.19121284.
8
Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?基于 DSM-5 的阿片类药物使用障碍的计量化治疗：我们能否使阿片类药物治疗更有效？
Addiction. 2019 Aug;114(8):1346-1353. doi: 10.1111/add.14546. Epub 2019 Jan 30.
9
Neurobiology of addiction: a neurocircuitry analysis.成瘾的神经生物学：神经回路分析
Lancet Psychiatry. 2016 Aug;3(8):760-773. doi: 10.1016/S2215-0366(16)00104-8.
10
Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study.海洛因依赖的长期死亡率、缓解情况、犯罪行为及精神疾病共病：澳大利亚治疗结果研究的11年随访结果
Addiction. 2015 Jun;110(6):986-93. doi: 10.1111/add.12860. Epub 2015 Mar 2.
Zotero 插件